Price Action Report: ACADIA Pharmaceuticals Inc.’s Trend Down, Especially After Today’s Weak Session

Price Action Report: ACADIA Pharmaceuticals Inc.'s Trend Down, Especially After Today's Weak Session

The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a huge mover today! The stock decreased 2.72% or $0.89 during the last trading session, hitting $31.81. About 2.40M shares traded hands or 27.66% up from the average. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has risen 84.30% since February 29, 2016 and is uptrending. It has outperformed by 73.87% the S&P500.
The move comes after 5 months negative chart setup for the $3.70B company. It was reported on Oct, 1 by Barchart.com. We have $29.90 PT which if reached, will make NASDAQ:ACAD worth $222.00M less.

Analysts await ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report earnings on November, 3. They expect $-0.60 EPS, down 53.85% or $0.21 from last year’s $-0.39 per share. After $-0.63 actual EPS reported by ACADIA Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Out of 4 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. ACADIA Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Sunday, August 9 the stock rating was maintained by Cowen & Co with “Outperform”. The rating was upgraded by Piper Jaffray to “Overweight” on Friday, January 22. The firm earned “Buy” rating on Friday, August 7 by Needham. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has “Overweight” rating given on Friday, August 7 by Piper Jaffray. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Hold” rating by Vetr on Monday, August 10. The rating was upgraded by Piper Jaffray to “Neutral” on Thursday, August 27. The firm has “Buy” rating given on Friday, September 4 by JP Morgan. The firm has “Market Perform” rating by Leerink Swann given on Tuesday, May 3. Piper Jaffray downgraded the stock to “Neutral” rating in Friday, August 7 report.

According to Zacks Investment Research, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.”

Insitutional Activity: The institutional sentiment decreased to 1.02 in 2016 Q2. Its down 0.31, from 1.33 in 2016Q1. The ratio turned negative, as 32 funds sold all ACADIA Pharmaceuticals Inc. shares owned while 68 reduced positions. 41 funds bought stakes while 61 increased positions. They now own 104.57 million shares or 4.71% less from 109.74 million shares in 2016Q1.
Northern holds 408,327 shares or 0% of its portfolio. New York State Common Retirement Fund has 193,179 shares for 0.01% of their US portfolio. Research holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 100 shares. Millennium Management Lc owns 83,097 shares or 0.01% of their US portfolio. Geode Lc holds 0.01% or 648,089 shares in its portfolio. The New York-based Comml Bank Of New York Mellon has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). The Texas-based Dimensional Fund L P has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Moreover, Finemark Bank & Trust has 0% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 235 shares. The Maryland-based Profund Advisors Ltd Liability Co has invested 0.08% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Blackrock Fund Advsr holds 0.02% or 2.34 million shares in its portfolio. Investors has invested 0.03% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). California Pub Employees Retirement Sys last reported 0.01% of its portfolio in the stock. Tower Research Cap Ltd Com (Trc) owns 4,205 shares or 0.01% of their US portfolio. Waddell Reed Fincl Incorporated owns 1.84M shares or 0.13% of their US portfolio. Huntington Savings Bank accumulated 0% or 76 shares.

Insider Transactions: Since April 18, 2016, the stock had 2 buys, and 2 insider sales for $41.34 million net activity. $43.00 million worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares were bought by BAKER BROS. ADVISORS LP. Shares for $560,033 were sold by Baity Glenn. The insider Iversen Leslie L sold 33,697 shares worth $1.13M. $32,970 worth of shares were bought by HARRIGAN EDMUND on Tuesday, August 16.

More recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: Schaeffersresearch.com which released: “Options Traders Bet On ACADIA Pharmaceuticals Inc. (ACAD) Breaking Lower” on September 30, 2016. Also Fool.com published the news titled: “Better Buy: ACADIA Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc.” on September 03, 2016. Fool.com‘s news article titled: “Why ACADIA Pharmaceuticals Tumbled 13.3% in August” with publication date: September 11, 2016 was also an interesting one.

ACAD Company Profile

ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment